Regular Article
Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata

https://doi.org/10.1053/jhin.2000.0918Get rights and content

Abstract

In a retrospective study (1 January 1992–12 December 1998), we investigated population characteristics and outcome in critically ill patients with fungaemia involving C. albicans (n=41) andC. glabrata (n=15). Patients with C. glabrata fungaemia were significantly older compared with patients in the C. albicans group (P=0.024). There were no other differences in population characteristics or severity of illness. Logistic regression analysis showed age (P=0.021), the presence of a polymicrobial blood stream infection (P=0.039), and renal failure (P=0.044) to be independent predictors of mortality. There was no significant difference in in-hospital mortality between the C. glabrata and C. albicans groups (60.0% vs. 41.5%;P=0.24). Since age was an independent predictor of mortality, the trend towards a higher mortality in patients with C. glabrata can be explained by this population being significantly older. In conclusion, we found no difference in mortality between patients with fungaemia involving C. albicans and C. glabrata.

References (28)

  • O Ekenna et al.

    Natural history of blood stream infections in burn patient population: the importance of candidemia

    Am J Infect Control

    (1993)
  • BS Shakir et al.

    Relative effectiveness of various yeasts, Candida spp. and Torulopsis glabrata, for inducing palatal infection in the Wistar rat

    Arch Oral Biol

    (1983)
  • E Cornwell et al.

    The pattern of fungal infections in critically ill surgical patients

    Am Surg

    (1995)
  • GJ Slotman et al.

    Fungal sepsis: multisite colonization versus fungemia

    Am Surg

    (1994)
  • J Nolla-Salas et al.

    Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy

    Intensive Care Med

    (1997)
  • PJ Eubanks et al.

    Candida sepsis in surgical patients

    Am J Surg

    (1993)
  • A Vos et al.

    Candidemia in intensive care unit patients: Risk factors for mortality

    Infection

    (1997)
  • Y Cohen et al.

    Prognosis factors in candidemia in nonneutropenic critically-ill patients [abstract no. J-140]

    (1998)
  • MH Nguyen et al.

    The changing face of candidemia: Emergence of non- Candida albicans species and antifungal resistance

    Am J Med

    (1996)
  • MH Nguyen et al.

    Therapeutic approaches in patients with candidemia

    Arch Intern Med

    (1995)
  • D Abi-Said et al.

    The epidemiology of hematogenous candidiasis caused by different Candida species

    Clin Infect Dis

    (1997)
  • SV Komshian et al.

    Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome

    Rev Infect Dis

    (1989)
  • WA Knauss et al.

    APACHE II: A severity of disease classification system

    Crit Care Med

    (1985)
  • JL Vincent et al.

    Epi-demiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care

    Intensive Care Med

    (1998)
  • Cited by (63)

    • Candida tropicalis burn wound sepsis: A series of histopathology-confirmed cases

      2018, Intensive and Critical Care Nursing
      Citation Excerpt :

      The prophylactic use of fluconazole inhibits the growth of Candida albicans. However, this practice has been proven to select for non-albicans species instead such as Candida glabrata and C. tropicalis (Blot et al., 2006; Blot et al., 2001; Ma, 2005). Candida tropicalis has been regarded as an important cause of fungaemia and invasive Candida inflammation in patients with sepsis (Dong et al., 2015).

    View all citing articles on Scopus
    f1

    Author for correspondence: Stijn Blot, Department of Intensive Care, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium. Tel.: 0032/9/240 27 75; Fax: 0032/9/240 49 95; E-mail:[email protected]

    View full text